Press releaseGlobe Newswire
Vivos
RDGL · OTC
$0.0463−$0.0015 (−3.14%)TodayMarket closed ·
Prev close $0.0478
Latest news
- Press releaseGlobe Newswire
Vivos Inc. Achieves Two Major Operational Milestones: First IsoPet® Shipments from New U.S. Production Facility and Authorization from India’s Nuclear Regulatory Authority for International Manufacturing Center
- Press releaseGlobe Newswire
Vivos Inc. (OTCQB: RDGL) Reports Second Quarter 2026 Progress and Corporate Update - Correction
- Press releaseGlobe Newswire
Vivos Inc. (OTCQB: RDGL) Reports Second Quarter 2026 Progress and Corporate Update
- Press releaseGlobe Newswire
Vivos Inc. (OTCQB: RDGL) Receives U.S. FDA Approval for Investigational Device Exemption (IDE) to Initiate Human Clinical Feasibility Study for RadioGel® Precision Radionuclide Therapy™
- News
Vivos Gets State Of Washington Radioactive Materials License To Manufacture IsoPet
- Press releaseGlobe Newswire
Vivos Inc. Announces Receipt of Washington State Radioactive Materials License for IsoPet® Manufacturing
- Press releaseGlobe Newswire
Vivos Inc. (OTCQB: RDGL) submits Early Feasibility Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel® Precision Radionuclide Therapy™
- Press releaseGlobe Newswire
Vivos Inc. Announces Significant Progress Toward FDA Investigational Device Exemption (IDE) Submission for RadioGel® Precision Radionuclide Therapy™
- Press releaseGlobe Newswire
Vivos Inc Updates Human Therapy Progress in India
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.